- Home
- ARDX vs ACP Comparison
ARDX vs ACP Comparison
Compare ARDX & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- ACP
- Stock Information
- Founded
- ARDX 2007
- ACP 2010
- Country
- ARDX United States
- ACP United States
- Employees
- ARDX N/A
- ACP N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- ARDX Health Care
- ACP Finance
- Exchange
- ARDX Nasdaq
- ACP Nasdaq
- Market Cap
- ARDX 882.9M
- ACP 737.8M
- IPO Year
- ARDX 2014
- ACP N/A
- Fundamental
- Price
- ARDX $4.29
- ACP $5.93
- Analyst Decision
- ARDX Strong Buy
- ACP
- Analyst Count
- ARDX 9
- ACP 0
- Target Price
- ARDX $10.17
- ACP N/A
- AVG Volume (30 Days)
- ARDX 4.3M
- ACP 337.9K
- Earning Date
- ARDX 08-04-2025
- ACP 01-01-0001
- Dividend Yield
- ARDX N/A
- ACP 17.79%
- EPS Growth
- ARDX N/A
- ACP N/A
- EPS
- ARDX N/A
- ACP N/A
- Revenue
- ARDX $361,706,000.00
- ACP N/A
- Revenue This Year
- ARDX $11.39
- ACP N/A
- Revenue Next Year
- ARDX $32.84
- ACP N/A
- P/E Ratio
- ARDX N/A
- ACP N/A
- Revenue Growth
- ARDX 127.33
- ACP N/A
- 52 Week Low
- ARDX $3.21
- ACP $5.55
- 52 Week High
- ARDX $7.18
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- ARDX 51.49
- ACP 51.47
- Support Level
- ARDX $4.27
- ACP $5.86
- Resistance Level
- ARDX $4.48
- ACP $5.98
- Average True Range (ATR)
- ARDX 0.19
- ACP 0.03
- MACD
- ARDX -0.03
- ACP -0.01
- Stochastic Oscillator
- ARDX 15.84
- ACP 54.17
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.